<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959969</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000260</org_study_id>
    <nct_id>NCT03959969</nct_id>
  </id_info>
  <brief_title>Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery</brief_title>
  <official_title>Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial assessing the utility of an educational video on pain
      management after a cesarean section to reduce opioid use. The educational video will be shown
      during the patient's postpartum stay and the amount of opioid and adjunct medications will be
      assessed in those who watched the video compared to those who received the standard of care
      discharge instructions without the video. Participants will be contacted 7 and 14 days after
      cesarean birth (post operative day number 7 and number 14) to complete a telephone survey on
      their overall pain management and to determine how many opioid tablets have been used.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oxycodone tablets used seven days after cesarean delivery</measure>
    <time_frame>7 days after cesarean delivery (postpartum day number 7)</time_frame>
    <description>This is the total number of oxycodone tablets used by participants in each arm seven days after cesarean delivery (postpartum day number 7).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of oxycodone tablets used fourteen days after cesarean delivery</measure>
    <time_frame>A total of 14 days after cesarean delivery (postpartum day number 14)</time_frame>
    <description>This is the total number of oxycodone tablets used by participants in each arm fourteen days after cesarean delivery (postpartum day number 14).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment score from numeric pain intensity scale at seven days after cesarean delivery</measure>
    <time_frame>7 days after cesarean delivery (postpartum day number 7)</time_frame>
    <description>Using an universal pain assessment tool of a numeric pain intensity scale, patients will be asked their pain score seven days after cesarean delivery (postpartum day 7). The numeric pain intensity scale is 0-10, with 0 being no pain and 10 being the worst pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunct medication use at seven days after cesarean delivery</measure>
    <time_frame>7 days after cesarean delivery (postpartum day number 7)</time_frame>
    <description>This is to determine use of adjunct medications such as ibuprofen and Tylenol in the participants in both arms, seven days after cesarean delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall pain management satisfaction using Likert scale seven days after cesarean delivery</measure>
    <time_frame>7 days after cesarean delivery (postpartum day number 7)</time_frame>
    <description>Assessment of overall pain management satisfaction seven days after cesarean delivery (postpartum day number 7) with five point Likert scale. The Likert scale ranges from extremely satisfied with pain management to extremely dissatisfied with pain management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment score from numeric pain intensity scale at fourteen days after cesarean delivery</measure>
    <time_frame>14 days after cesarean delivery (postpartum day number 14)</time_frame>
    <description>Using an universal pain assessment tool of a numeric pain intensity scale, patients will be asked their pain score fourteen days after cesarean delivery (postpartum day 14).The numeric pain intensity scale is 0-10, with 0 being no pain and 10 being the worst pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunct medication use at fourteen days after cesarean delivery</measure>
    <time_frame>14 days after cesarean delivery (postpartum day number 14)</time_frame>
    <description>This is to determine use of adjunct medications such as ibuprofen and Tylenol in the participants in both arms, fourteen days after cesarean delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall pain management satisfaction using Likert scale fourteen days after cesarean delivery</measure>
    <time_frame>14 days after cesarean delivery (postpartum day number 14)</time_frame>
    <description>Assessment of overall pain management satisfaction fourteen days after cesarean delivery (postpartum day number 14) with five point Likert scale. The Likert scale ranges from extremely satisfied with pain management to extremely dissatisfied with pain management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of oxycodone tablets used inpatient</measure>
    <time_frame>3 days</time_frame>
    <description>Total oxycodone tablets used during patient's inpatient stay after cesarean delivery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Opioid Use, Unspecified</condition>
  <arm_group>
    <arm_group_label>Educational Video Recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be shown educational video on pain management after cesarean delivery on postpartum day number 2. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Recipients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given standard of care discharge instructions for pain management on postpartum day number 3, when discharged. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational video</intervention_name>
    <description>An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.</description>
    <arm_group_label>Educational Video Recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.</description>
    <arm_group_label>Standard of Care Recipients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.</description>
    <arm_group_label>Educational Video Recipients</arm_group_label>
    <arm_group_label>Standard of Care Recipients</arm_group_label>
    <other_name>Advil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.</description>
    <arm_group_label>Educational Video Recipients</arm_group_label>
    <arm_group_label>Standard of Care Recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 years of age

          -  Underwent repeat or primary C-section

          -  Literate in English Language

        Exclusion Criteria:

          -  Complicated cesarean section including cesarean hysterectomy, bowel injury, bladder
             injury, and/or take-back

          -  History of opioid use disorder and/or on chronic opiates in pregnancy

          -  Contraindications to NSAIDS or acetaminophen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Iqbal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neggin Mokhtari, MD</last_name>
    <phone>202-877-3067</phone>
    <email>neggin.mokhtari@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neggin Mokhtari, MD</last_name>
      <phone>202-877-3067</phone>
      <email>neggin.mokhtari@medstar.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prabhu M, McQuaid-Hanson E, Hopp S, Burns SM, Leffert LR, Landau R, Lauffenburger JC, Choudhry NK, Kaimal A, Bateman BT. A Shared Decision-Making Intervention to Guide Opioid Prescribing After Cesarean Delivery. Obstet Gynecol. 2017 Jul;130(1):42-46. doi: 10.1097/AOG.0000000000002094.</citation>
    <PMID>28594762</PMID>
  </reference>
  <reference>
    <citation>Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, Huybrechts KF, Clancy CR, Hopp SB, Ecker JL, Ende H, Grewe K, Raposo Corradini B, Schoenfeld RE, Sankar K, Day LJ, Harris L, Booth JL, Flood P, Bauer ME, Tsen LC, Landau R, Leffert LR. Patterns of Opioid Prescription and Use After Cesarean Delivery. Obstet Gynecol. 2017 Jul;130(1):29-35. doi: 10.1097/AOG.0000000000002093.</citation>
    <PMID>28594763</PMID>
  </reference>
  <reference>
    <citation>Ismail S, Shahzad K, Shafiq F. Observational study to assess the effectiveness of postoperative pain management of patients undergoing elective cesarean section. J Anaesthesiol Clin Pharmacol. 2012 Jan;28(1):36-40. doi: 10.4103/0970-9185.92432.</citation>
    <PMID>22345943</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee Opinion No. 742 Summary: Postpartum Pain Management. Obstet Gynecol. 2018 Jul;132(1):252-253. doi: 10.1097/AOG.0000000000002711.</citation>
    <PMID>29939935</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Sara N. Iqbal</investigator_full_name>
    <investigator_title>Maternal Fetal Medicine Fellowship Program Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

